Clinical Trial

A Study to Examine Anktiva for the Treatment of COVID-19.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-13; most recent amendment 2026-05-08.
Trial Details
NCT Number NCT07123727
Lead Sponsor ImmunityBio, Inc.
Conditions Long COVID, Long COVID Syndrome, Long Covid 19
Enrollment 40 participants
Start Date 2025-09-04
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-13